TRIBE2 results and toxicity

doi:10.1016/S1470-2045(20)30270-9

Comment

. 2020 Jun;21(6):e298.

doi: 10.1016/S1470-2045(20)30270-9.

TRIBE2 results and toxicity

Jianwei Zhang¹, Yue Cai¹, Xiaoyu Xie¹, Huabin Hu¹, Yanhong Deng²

Affiliations

¹ Department of Medical Oncology, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou 510655, Guangdong, China.
² Department of Medical Oncology, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou 510655, Guangdong, China. Electronic address: dengyanh@mail.sysu.edu.cn.

PMID: 32502450
DOI: 10.1016/S1470-2045(20)30270-9

Comment

TRIBE2 results and toxicity

Jianwei Zhang et al. Lancet Oncol. 2020 Jun.

. 2020 Jun;21(6):e298.

doi: 10.1016/S1470-2045(20)30270-9.

Authors

Jianwei Zhang¹, Yue Cai¹, Xiaoyu Xie¹, Huabin Hu¹, Yanhong Deng²

Affiliations

¹ Department of Medical Oncology, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou 510655, Guangdong, China.
² Department of Medical Oncology, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou 510655, Guangdong, China. Electronic address: dengyanh@mail.sysu.edu.cn.

PMID: 32502450
DOI: 10.1016/S1470-2045(20)30270-9

No abstract available

PubMed Disclaimer

Comment in

TRIBE2 results and toxicity.
Avallone A, Giuliani F. Avallone A, et al. Lancet Oncol. 2020 Jun;21(6):e299. doi: 10.1016/S1470-2045(20)30273-4. Lancet Oncol. 2020. PMID: 32502451 No abstract available.
TRIBE2 results and toxicity - Authors' reply.
Antoniotti C, Cremolini C, Rossini D, Falcone A. Antoniotti C, et al. Lancet Oncol. 2020 Jun;21(6):e300-e301. doi: 10.1016/S1470-2045(20)30288-6. Lancet Oncol. 2020. PMID: 32502452 No abstract available.

Comment on

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. Cremolini C, et al. Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9. Lancet Oncol. 2020. PMID: 32164906 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

Supplementary concepts

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

TRIBE2 results and toxicity

Affiliations

TRIBE2 results and toxicity

Authors

Affiliations

Comment in

Comment on

Similar articles

Publication types

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources

Full Text Sources

Medical

Comment in

Comment on

Similar articles

Publication types

MeSH terms

Substances

Supplementary concepts

Related information

LinkOut - more resources

Full Text Sources

Medical